Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia (Q53389797)

13 May 2018

title

Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia (English)

1 reference

https://api.crossref.org/works/10.3109/10428194.2012.660631

23 December 2024

main subject

phase I clinical trial

0 references

1

Eunice S. Wang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22280537

23 December 2024

4

Donna Hogge

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22280537

23 December 2024

author name string

Karen Yee

2

1 reference

13 May 2018

Liang Piu Koh

3

1 reference

13 May 2018

Sari Enschede

5

1 reference

13 May 2018

Matthew Dudley

7

1 reference

13 May 2018

Keith Glaser

8

1 reference

13 May 2018

Evelyn McKeegan

9

1 reference

13 May 2018

Xiaohui Li

11

1 reference

13 May 2018

Rajendra Pradhan

12

1 reference

13 May 2018

Wendy Stock

13

1 reference

13 May 2018

Dawn M. Carlson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22280537

23 December 2024

Daniel H. Albert

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22280537

23 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22280537

23 December 2024

publication date

1 March 2012

1 reference

13 May 2018

full work available at URL

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2012.660631

1 reference

https://api.crossref.org/works/10.3109/10428194.2012.660631

23 December 2024

1 reference

13 May 2018

volume

53

1 reference

13 May 2018

issue

8

1 reference

13 May 2018

page(s)

1543-1551

1 reference

13 May 2018

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660631

21 January 2018

Acute myeloid leukemia

3

1 reference

https://api.crossref.org/works/10.3109/10428194.2012.660631

Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse

23 December 2024

9

1 reference

https://api.crossref.org/works/10.3109/10428194.2012.660631

Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer

23 December 2024

18

1 reference

https://api.crossref.org/works/10.3109/10428194.2012.660631

23 December 2024

Identifiers

1 reference

13 May 2018

1 reference

13 May 2018